Medtronic Stock News

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) s

According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) s

We find significant appeal in dividend stocks as relatively low interest rates for developed markets around the globe plague income-oriented investors, while sustained inflation threatens to erode our

Both are two exceptional growth stocks -- but which is the better choice for investors now?

Both are two exceptional growth stocks -- but which is the better choice for investors now?

Medtronic plc (NYSE: MDT ) announced final findings from a study that confirmed the effectiveness of the GI Genius intelligent endoscopy module. GI Genius uses AI to aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC). The study published in Gastroenterology found … Full story available on Benzinga.com

Medtronic (MDT) announced final data from an international multi-center study on Wednesday to claim that its GI Genius endoscopy module used in colonoscopy can lead to a 50% reduction…

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings and strong market share gains.

We provide a summary of upcoming ex-dividend dates in a quick reference table.

VOO and other S&P 500 index funds report data that can lag for as much as two months behind. We compare metrics of VOO as of January 31, 2022 and those of SPY now to see how they differ.

SAN FRANCISCO , March 11, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Central Venous Catheters (CVCs) - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 7; Released: February 2022 Executive Pool: 4019 Companies: 61 - Players covered include Amecath; AngioDynamics Inc.; B. Braun Melsungen AG; Bactiguard AB; Becton, Dickinson and Company; COOK MEDICAL LLC; Edwards Lifesciences Corporation; Guangdong Baihe Medical Technology Co., Ltd; ICU Medical, Inc.; Insung Medical Co.

The "Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com''s offering. Carotid and Renal Artery Stents (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area. The model discusses in detail the impact of COVID-19 on Carotid and Renal Artery Stents market for the year 2020 and beyond. Three types of therapies are recommended for carotid stenosis. These therapies include medication, endovascular intervention, and endarterectomy. Endarterectomy is recommended over stenting to patients who are suffering from stenosis (>70%) and have had symptoms for the last six months to a year. It is not recommended to individuals with 50% or less stenosis in the carotid artery. Endovascular therapy is … Full story available on Benzinga.com